Trials / Recruiting
RecruitingNCT07496450
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of mRNA-1018-H5 Pandemic Influenza Vaccine in Adults ≥18 Years of Age
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,000 (estimated)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-1018-H5 | Sterile liquid for injection. |
| BIOLOGICAL | Placebo | Sterile liquid for injection. |
Timeline
- Start date
- 2026-03-23
- Primary completion
- 2027-01-28
- Completion
- 2027-01-28
- First posted
- 2026-03-27
- Last updated
- 2026-04-03
Locations
36 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07496450. Inclusion in this directory is not an endorsement.